Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.
1. A method of treating or ameliorating an immune cell-associated pathology in a subject for whom suppression of immune response is desired, wherein the immune cell is a T cell, comprising administering to the subject a therapeutically effective amount of a neutralizing anti-Glucocorticoid-Induced TNF Receptor Ligand antibody (anti-GITRL antibody), wherein the anti-GITRL antibody is a 5F1 antibody, a 10F12 antibody, or an antigen-binding fragment thereof, and wherein the anti-GITRL antibody treats or ameliorates the immune cell-associated pathology by blocking GITRL binding to the Glucocorticoid-Induced TNF Receptor (GITR) on effector T cells, and wherein the immune cell-associated pathology is selected from the group consisting of rheumatoid arthritis, encephalomyelitis, multiple sclerosis, osteoarthritis, autoimmune gastritis, psoriasis and other inflammatory dermatoses, asthma, allergy, organ transplant rejection, graft-versus-host disease, and inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
2. The method of claim 1 , wherein the method comprises administering the anti-GITRL antibody such that the susceptibility of effector T cells in the subject to suppression by CD4 + CD25 + regulatory T cells is maintained.
3. The method of claim 1 , wherein the immune cell-associated pathology is multiple sclerosis.
4. The method of claim 1 , where in the effector T cells are CD4 + CD25 − T cells.